Fact CheckerSign in

NCT06321432Active, not recruiting

Intensive Weight Loss Intervention Versus Usual Care for Adults With Obesity

Intensive Weight Loss Intervention Versus Usual Care for Adults With Obesity: the LightCARE Randomised Trial. Lighthouse Consortium on Obesity Management (LightCOM) Trial no 2

Source: ClinicalTrials.gov · Last updated 10 Feb 2026

Brief summary (registry, in English)

In this trial, the aim is to assess the clinical benefits and harms, as well as cost-effectiveness of an intensive weight loss (IWL) intervention that includes total dietary replacements, behavioural support and weight-loss medication compared with existing weight management programmes within primary care for people with obesity class I or uncomplicated obesity class II or higher.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
480 (actual)
First submitted
13 Mar 2024
Start date
5 Jun 2024
Primary completion date
Jan 2028
Lead sponsor
Carsten Dirksen
Diseases
Obesity
NCT number
NCT06321432

What you commit to

  • Study type: Interventional
  • Participants enrolled: 480
  • From 5 Jun 2024 to the primary completion date, Jan 2028
  • 10 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior bariatric surgery, not including laparoscopic gastric banding, intragastric balloons or duodenal-jejunal bypass sleeve (Endobarrier™ or similar) if the device has been removed \>1 year before screening.

Other illness

  • Has severe and complex obesity, i.e., obesity class II (BMI≥35 if white or 32.5 if non-white) with one or more of these specific adiposity-related comorbidities: cardiovascular disease, type 2 diabetes, hypertension, non-alcoholic steatosis, or sleep apnoea (Appendix 1).
  • Currently being treated for cancer other than oestrogen antagonist therapy or non-melanoma skin cancer.
  • Diagnosis or treatment for eating disorder within the last 6 months.
  • Any other disease that markedly compromises the participant's ability to adhere to the treatment programme or follow-up or is likely to mean that weight loss will not improve the person's length or quality of life, such as conditions limiting life expectancy.
  • Conditions that contraindicate or complicate total diet replacement (including type 1 diabetes or other diabetes requiring any insulin therapy, phenylketonuria, or other conditions requiring special diets).
  • Conditions that contraindicate or complicate GLP-1 or GIP agonist treatment (including history of pancreatitis)

Other

  • Intending to become pregnant in the next two years, or pregnant, or breastfeeding.
  • Use of WLM or GLP-1 agonist treatment within the last 3 months.
  • Taking part in other research involving multidisciplinary obesity treatment that would compromise participation in this trial.
  • Another member of the household enrolled in the trial.

Who the study is looking for

  • Age ≥18 years and ≤60 years old at screening.
  • BMI ≥30 kg/m2 or ≥27.5 kg/m2 in people with South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds (as reported by the participants).
  • Informed consent.

Criteria the registry did not label

  • Please note that participants need to be invited in order to take part in the trial.

Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
The Department of Medicine and the Gastro Unit, Copenhagen University Hospital - Amager and Hvidovre
Coordinator of this site? Confirm its status
CopenhagenDenmarkUnknown status
Frederiksberg kommune: Social-, Sundheds- og Arbejdsmarkedsområdet
Coordinator of this site? Confirm its status
FrederiksbergDenmarkUnknown status
The Parker Institute, Copenhagen University Hospital - Bispebjerg and Frederiksberg
Coordinator of this site? Confirm its status
FrederiksbergDenmarkUnknown status
Hvidovre kommune: Center for Sundhed og Ældre, Hvidovre Sundhedscenter, Sundhed og Forebyggelse
Coordinator of this site? Confirm its status
HvidovreDenmarkUnknown status
Gladsaxe kommune: Social- og Sundhedsforvaltningen, Sundhed og Rehabilitering
Coordinator of this site? Confirm its status
SøborgDenmarkUnknown status
West Midlands RRDN
Coordinator of this site? Confirm its status
BirminghamUnited KingdomUnknown status
South West Peninsula RDN, Exeter
Coordinator of this site? Confirm its status
ExeterUnited KingdomUnknown status
Yorkshire and Humber RRDN (Leeds, Sheffield and Hull)
Coordinator of this site? Confirm its status
LeedsUnited KingdomUnknown status
North West RRDN
Coordinator of this site? Confirm its status
ManchesterUnited KingdomUnknown status
East of England RRDN
Coordinator of this site? Confirm its status
NorwichUnited KingdomUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.